Apollon Formularies PLC (AQSE:APOL) said it appointed Dr Herbert Fritsche to the board of directors, adding director Kevin Sheil will step aside to pursue other interests.
Fritsche is a clinical chemist and former professor of laboratory medicine and is chief of the Clinical Chemistry section at The University of Texas, MD Anderson Cancer Center in Houston.
Previously he served as an invited consultant to the Food and Drug Administration (FDA), the National Cancer Institute and other major international diagnostic companies.
"Dr Fritsche is a highly respected international authority in clinical chemistry and one of the world's leading experts on cancer biomarkers,” said Stephen D. Barnhill, executive chairman and chief executive of Apollon Formularies.
During his career, Dr Fritsche won several awards, including the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry and the Abbott-ISOBM Award for Outstanding Research in Oncology.
Fritsche has also published over 200 peer reviewed scientific papers, book chapters and articles and holds three patents with two pending.
He is experienced in FDA validation and the clearance process and is a participant in almost every commercial serum cancer marker currently in use in the US, the statement said.